Stockholm-based biotech firm Swedish Orphan Biovitrum (STO: SOBI) has announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorization application for efanesoctocog alfa.
Also known as Sobi, the company describes efanesoctocog alfa as a new class of high-sustained FVIII developed for the treatment of people with hemophilia A of all age groups.
The application is based on data from the pivotal XTEND-1 Phase III study in adults and adolescents, and the XTEND-Kids pediatric study in patients of at least 12 years of age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze